Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leu...
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 20
- Registration Number
- NCT06554626
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06548230
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 98
- Registration Number
- NCT06544109
- Locations
- 🇨🇳
Qiu huiying, Suzhou, Jiangsu, China
Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Hospital Municipal São José
- Target Recruit Count
- 100
- Registration Number
- NCT06537843
- Locations
- 🇧🇷
Hospital Ophir Loyola, Belem, Brazil
🇧🇷Hospital de Clínicas da UFPR, Curitiba, Brazil
🇧🇷Hospital Amaral Carvalho, Jaú, Brazil
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-Line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-Treatment Period.
- Conditions
- Interventions
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06524375
- Locations
- 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸University Cancer and Blood Center, LLC, Athens, Georgia, United States
🇺🇸American Oncology Partners of Maryland, Pa, Bethesda, Maryland, United States
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06522386
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Conditions
- Interventions
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 100
- Registration Number
- NCT06520098
- Locations
- 🇺🇸
Kansas City VA Medical Center, Kansas City, MO, Kansas City, Missouri, United States
🇺🇸Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States
🇺🇸San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States
A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-24
- Target Recruit Count
- 528
- Registration Number
- NCT06516978
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
- Conditions
- Interventions
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT06514261
- Locations
- 🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
- Conditions
- Interventions
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2024-11-29
- Target Recruit Count
- 37
- Registration Number
- NCT06511882
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.